154 related articles for article (PubMed ID: 31493284)
1. In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.
Asgari A; Sharifzadeh S; Ghaderi A; Hosseini A; Ramezani A
Mol Biol Rep; 2019 Dec; 46(6):6205-6213. PubMed ID: 31493284
[TBL] [Abstract][Full Text] [Related]
2. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
5. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
Miura D; Yoneyama K; Furuhata Y; Shimizu K
J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
9. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.
Misumi T; Tanabe K; Fujikuni N; Ohdan H
PLoS One; 2018; 13(10):e0204880. PubMed ID: 30321186
[TBL] [Abstract][Full Text] [Related]
11. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
12. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
13. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A; Signorino E; Evangelista A; Brusa D; Mistrangelo M; Polimeni MA; Spadi R; Donadio M; Ciuffreda L; Matera L
J Transl Med; 2008 May; 6():25. PubMed ID: 18485193
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.
Kajitani K; Tanaka Y; Arihiro K; Kataoka T; Ohdan H
Breast Cancer Res Treat; 2012 Jul; 134(1):139-55. PubMed ID: 22261932
[TBL] [Abstract][Full Text] [Related]
15. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
[TBL] [Abstract][Full Text] [Related]
16. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Katsumi Y; Kuwahara Y; Tamura S; Kikuchi K; Otabe O; Tsuchiya K; Iehara T; Kuroda H; Hosoi H; Sugimoto T
Clin Cancer Res; 2008 Feb; 14(4):1192-9. PubMed ID: 18281554
[TBL] [Abstract][Full Text] [Related]
18. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Mani A; Roda J; Young D; Caligiuri MA; Fleming GF; Kaufman P; Brufsky A; Ottman S; Carson WE; Shapiro CL
Breast Cancer Res Treat; 2009 Sep; 117(1):83-9. PubMed ID: 19051009
[TBL] [Abstract][Full Text] [Related]
20. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
